Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Beatriz Rebelo
Data de Publicação: 2021
Tipo de documento: Trabalho de conclusão de curso
Idioma: por
Título da fonte: Repositório Institucional da UFAM
Texto Completo: http://riu.ufam.edu.br/handle/prefix/5968
Resumo: Alzheimer's disease is considered the degenerative disease with the highest incidence in Brazil. It is responsible for social and economic damages to patients with the disease and their caregivers and family members. Characterized by neuronal atrophy and synapse loss, due to unknown pathophysiology, current medications are responsible for slowing the progression of the disease, since high dosages are required to obtain the therapeutic effect, a factor responsible for several adverse effects, and consequently abandonment of therapy. Nanotechnology is a promising tool for the pharmaceutical industry to improve current and future drugs for the treatment of various neurological disorders. This study aimed to describe the main nanotechnologies applied in the treatment of Alzheimer's disease, through a descriptive and qualitative bibliographic survey, in the main scientific platforms. The entire investigation was carried out in the English language from 2015 to 2021, the search terms were: “Nanoparticles”, “Drug delivery system”, “Alzheimer's disease”, “treatment of Alzheimer’s disease”. 10 articles were selected with in vitro and in vivo applications, aiming at the use of biomaterials as a tool for pharmacodynamic and pharmacokinetic improvement. The aforementioned studies have optimized the delivery of drug to the target of action and showed good neuronal activity.
id UFAM-1_5ad53cf38e482a6a3c2c2cdf41f3872e
oai_identifier_str oai:localhost:prefix/5968
network_acronym_str UFAM-1
network_name_str Repositório Institucional da UFAM
repository_id_str
spelling Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de AlzheimerNanopartículasDoença de AlzheimerNanotecnologiaIndústria farmacêuticaCIÊNCIAS DA SAÚDE: FARMÁCIAMelhoramento farmacocinéticoFarmacologiaBiodisponibilidadeDistúrbios neurológicosAlzheimer's disease is considered the degenerative disease with the highest incidence in Brazil. It is responsible for social and economic damages to patients with the disease and their caregivers and family members. Characterized by neuronal atrophy and synapse loss, due to unknown pathophysiology, current medications are responsible for slowing the progression of the disease, since high dosages are required to obtain the therapeutic effect, a factor responsible for several adverse effects, and consequently abandonment of therapy. Nanotechnology is a promising tool for the pharmaceutical industry to improve current and future drugs for the treatment of various neurological disorders. This study aimed to describe the main nanotechnologies applied in the treatment of Alzheimer's disease, through a descriptive and qualitative bibliographic survey, in the main scientific platforms. The entire investigation was carried out in the English language from 2015 to 2021, the search terms were: “Nanoparticles”, “Drug delivery system”, “Alzheimer's disease”, “treatment of Alzheimer’s disease”. 10 articles were selected with in vitro and in vivo applications, aiming at the use of biomaterials as a tool for pharmacodynamic and pharmacokinetic improvement. The aforementioned studies have optimized the delivery of drug to the target of action and showed good neuronal activity.A doença de Alzheimer é uma enfermidade multifatorial considerada a doença degenerativa de maior incidência no Brasil, sendo responsável por danos sociais e econômicos para o portador da patologia e seus familiares. Caracterizada pela atrofia neuronal e perda de sinapses, sua fisiopatologia não foi elucidada completamente e os medicamentos atuais são responsáveis por retardar a progressão da doença. Entre os medicamentos empregados, os inibidores de acetilcolinesterase são responsáveis por diversos efeitos adversos e, consequentemente, o abandono da terapêutica. A nanotecnologia mostra-se um instrumento promissor para a indústria farmacêutica no aperfeiçoamento dos medicamentos atuais e futuros para o tratamento de diversos distúrbios neurológicos, aumentando a biodisponibilidade e diminuindo os efeitos adversos. O presente estudo teve como objetivo descrever as principais nanotecnologias aplicadas no tratamento da doença de Alzheimer, por meio de levantamento bibliográfico descritivo e qualitativo, nas principais plataformas científicas. Toda investigação foi realizada no idioma inglês no período de 2015 a 2021, os termos de pesquisa foram: “Nanoparticles”, “Drug delivery systems”, “Alzheimer's disease”, “treatment of Alzheimer’s disease” acompanhados da conjunção “and” com variação de termos. Foram selecionados 10 artigos científicos com aplicações in vitro e in vivo, visando o emprego de biomateriais como uma ferramenta para melhoramento farmacodinâmico e farmacocinético. Os estudos supracitados otimizaram a entrega de fármaco ao alvo de ação e apresentaram boa atividade neuronal.3Tutorial explicando todo o processo de depósito do documento.SimDESCONHECER O PROCESSO DE AUTODEPÓSITO.BrasilICET - Instituto de Ciências Exatas e Tecnologia (Itacoatiara)Manaus-AMFarmácia - Bacharelado - ItacoatiaraKaufmann, Giana Thaíshttp://lattes.cnpq.br/6176113716808731Campos, Ranierihttp://lattes.cnpq.br/5460360137477353Ghizoni, Cristiane Vizioli de Castrohttp://lattes.cnpq.br/1267518347915388https://orcid.org/0000-0002-9413-4215https://orcid.org/0000-0002-9413-4215https://orcid.org/0000-0002-4856-9875Rodrigues, Beatriz Rebelo2021-09-27T14:04:12Z2021-09-272021-09-27T14:04:12Z2021-07-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesishttp://riu.ufam.edu.br/handle/prefix/5968porBAYSAL, Ipek et al. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. Journal of Neural Transmission, v. 124, n. 1, p. 33-45, 2017. BINDA, Anna; MURANO, Carmen; RIVOLTA, Ilaria. Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a state-of-the-art (2017– 2020). International Journal of Nanomedicine, v. 15, p. 6113, 2020. BURNS, Alistair et al. Cause of death in Alzheimer's disease. Age and ageing, v. 19, n. 5, p. 341-344, 1990. CRUCHO, Carina IC; BARROS, Maria Teresa. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Materials Science and Engineering: C, v. 80, p. 771-784, 2017. CANO, Amanda et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine, v. 15, n. 12, p. 1239-1261, 2020. CANO, Amanda et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, v. 301, p. 62-75, 2019. DANEMAN, Richard; PRAT, Alexandre. The blood–brain barrier. Cold Spring Harbor perspectives in biology, v. 7, n. 1, p. a020412, 2015. ELNAGGAR, Yosra SR et al. Intranasal piperine-loaded chitosan nanoparticles as braintargeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. Journal of pharmaceutical sciences, v. 104, n. 10, p. 3544-3556, 2015. FILHO, Ronaldo Pontes Barreira and Barreira, Idalbenia V. Barbosa P. (2017) Doença de Alzheimer: Diagnóstico e Perspectivas, Gramma, p. 168. FARJADIAN, Fatemeh et al. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine, v. 14, n. 1, p. 93-126, 2019. FOND, Guillaume; MACGREGOR, Alexandra; MIOT, Stéphanie. Nanopsychiatry—the potential role of nanotechnologies in the future of psychiatry: a systematic review. European neuropsychopharmacology, v. 23, n. 9, p. 1067-1071, 2013. GNACH, Anna et al. Upconverting nanoparticles: assessing the toxicity. Chemical Society Reviews, v. 44, n. 6, p. 1561-1584, 2015. GOATE, Alison et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, v. 349, n. 6311, p. 704-706, 1991. GNACH, Anna et al. Upconverting nanoparticles: assessing the toxicity. Chemical Society Reviews, v. 44, n. 6, p. 1561-1584, 2015. GELDMACHER, David S. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Primary care companion to the Journal of Clinical Psychiatry, v. 9, n. 2, p. 113, 2007. HARDY, John; SELKOE, Dennis J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. science, v. 297, n. 5580, p. 353-356, 2002. HUNT, Reid; DE M. TAVEAU, René. On the physiological action of certain cholin derivatives and new methods for detecting cholin. The British Medical Journal, p. 1788- 1791, 1906. HU, Ye et al. Nanodevices in diagnostics. Wiley interdisciplinary reviews: Nanomedicine and Nanobiotechnology, v. 3, n. 1, p. 11-32, 2011. IGARTÚA, Daniela E. et al. Combined therapy for alzheimer’s disease: tacrine and PAMAM dendrimers co-administration reduces the side effects of the drug without modifying its activity. AAPS PharmSciTech, v. 21, n. 3, p. 1-14, 2020. KARTHIVASHAN, Govindarajan et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug delivery, v. 25, n. 1, p. 307- 320, 2018. KRISHNA, Kowthavarapu Venkata et al. Design and biological evaluation of lipoproteinbased donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS chemical neuroscience, v. 10, n. 9, p. 4124-4135, 2019. KAUR, Atinderpal et al. Memantine nanoemulsion: a new approach to treat Alzheimer’s disease. Journal of microencapsulation, v. 37, n. 5, p. 355-365, 2020. LEVY-LAHAD, Ephrat et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, v. 269, n. 5226, p. 973-977, 1995. LOVELL, M. A. et al. Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the neurological sciences, v. 158, n. 1, p. 47-52, 1998. MAHMOUDI, Masomeh et al. Preparation and characterization of memantine loaded polycaprolactone nanocapsules for Alzheimer’s disease. Journal of Porous Materials, v. 28, n. 1, p. 205-212, 2021. MASSOUD, Fadi; LÉGER, Gabriel C. Pharmacological treatment of Alzheimer disease. The Canadian Journal of Psychiatry, v. 56, n. 10, p. 579-588, 2011. MANSOORI, G. Ali; SOELAIMAN, TA Fauzi. Nanotechnology—an introduction for the standards community. Journal of ASTM International, v. 2, n. 6, p. 1-22, 2005. MISRA, Shubham et al. Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug delivery, v. 23, n. 4, p. 1434-1443, 2016. NIEMIROWICZ, K. et al. Magnetic nanoparticles as new diagnostic tools in medicine. Advances in medical sciences, v. 57, n. 2, p. 196-207, 2012. NOBLE, Wendy; POOLER, Amy M.; HANGER, Diane P. Advances in tau-based drug discovery. Expert opinion on drug discovery, v. 6, n. 8, p. 797-810, 2011. PANZA, Francesco et al. Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?. Annals of neurology, v. 85, n. 3, p. 303-315, 2019. PAULA, Vanessa de Jesus R. de et al. Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dementia & neuropsychologia, v. 3, p. 188-194, 2009. PINHEIRO, R. G. R. et al. RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer’s disease. Pharmaceutical Research, v. 37, n. 7, p. 1-12, 2020. ROCO, Mihail C. International strategy for nanotechnology research. Journal of nanoparticle Research, v. 3, n. 5, p. 353-360, 2001. ROSS, Callum et al. Liposome delivery systems for the treatment of Alzheimer’s disease. International journal of nanomedicine, v. 13, p. 8507, 2018. SILMAN, Israel; SUSSMAN, Joel L. Acetylcholinesterase:‘classical’and ‘nonclassical’functions and pharmacology. Current opinion in pharmacology, v. 5, n. 3, p. 293- 302, 2005. SKAPER, Stephen D. Alzheimer’s disease and amyloid: culprit or coincidence. Int Rev Neurobiol, v. 102, p. 277-316, 2012. TOMA, Henrique Eisi. Nanotecnologia molecular: materiais e dispositivos. Editora Blucher, 2016. VIMAL, Sunil Kumar et al. Self‐Therapeutic Nanoparticle That Alters Tau Protein and Ameliorates Tauopathy Toward a Functional Nanomedicine to Tackle Alzheimer's. Small, v. 16, n. 16, p. 1906861, 2020. WOLFRAM, Joy et al. Safety of nanoparticles in medicine. Current drug targets, v. 16, n. 14, p. 1671-1681, 2015. YIANNOPOULOU, Konstantina G.; PAPAGEORGIOU, Sokratis G. Current and future treatments in Alzheimer disease: an update. Journal of central nervous system disease, v. 12, p. 1179573520907397, 2020.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFAMinstname:Universidade Federal do Amazonas (UFAM)instacron:UFAM2021-12-01T04:42:01Zoai:localhost:prefix/5968Repositório InstitucionalPUBhttp://riu.ufam.edu.br/oai/requestopendoar:2021-12-01T04:42:01Repositório Institucional da UFAM - Universidade Federal do Amazonas (UFAM)false
dc.title.none.fl_str_mv Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
title Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
spellingShingle Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
Rodrigues, Beatriz Rebelo
Nanopartículas
Doença de Alzheimer
Nanotecnologia
Indústria farmacêutica
CIÊNCIAS DA SAÚDE: FARMÁCIA
Melhoramento farmacocinético
Farmacologia
Biodisponibilidade
Distúrbios neurológicos
title_short Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
title_full Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
title_fullStr Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
title_full_unstemmed Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
title_sort Inovações tecnológicas no setor farmacêutico: a nanotecnologia e suas aplicações no tratamento da doença de Alzheimer
author Rodrigues, Beatriz Rebelo
author_facet Rodrigues, Beatriz Rebelo
author_role author
dc.contributor.none.fl_str_mv Kaufmann, Giana Thaís
http://lattes.cnpq.br/6176113716808731
Campos, Ranieri
http://lattes.cnpq.br/5460360137477353
Ghizoni, Cristiane Vizioli de Castro
http://lattes.cnpq.br/1267518347915388
https://orcid.org/0000-0002-9413-4215
https://orcid.org/0000-0002-9413-4215
https://orcid.org/0000-0002-4856-9875
dc.contributor.author.fl_str_mv Rodrigues, Beatriz Rebelo
dc.subject.por.fl_str_mv Nanopartículas
Doença de Alzheimer
Nanotecnologia
Indústria farmacêutica
CIÊNCIAS DA SAÚDE: FARMÁCIA
Melhoramento farmacocinético
Farmacologia
Biodisponibilidade
Distúrbios neurológicos
topic Nanopartículas
Doença de Alzheimer
Nanotecnologia
Indústria farmacêutica
CIÊNCIAS DA SAÚDE: FARMÁCIA
Melhoramento farmacocinético
Farmacologia
Biodisponibilidade
Distúrbios neurológicos
description Alzheimer's disease is considered the degenerative disease with the highest incidence in Brazil. It is responsible for social and economic damages to patients with the disease and their caregivers and family members. Characterized by neuronal atrophy and synapse loss, due to unknown pathophysiology, current medications are responsible for slowing the progression of the disease, since high dosages are required to obtain the therapeutic effect, a factor responsible for several adverse effects, and consequently abandonment of therapy. Nanotechnology is a promising tool for the pharmaceutical industry to improve current and future drugs for the treatment of various neurological disorders. This study aimed to describe the main nanotechnologies applied in the treatment of Alzheimer's disease, through a descriptive and qualitative bibliographic survey, in the main scientific platforms. The entire investigation was carried out in the English language from 2015 to 2021, the search terms were: “Nanoparticles”, “Drug delivery system”, “Alzheimer's disease”, “treatment of Alzheimer’s disease”. 10 articles were selected with in vitro and in vivo applications, aiming at the use of biomaterials as a tool for pharmacodynamic and pharmacokinetic improvement. The aforementioned studies have optimized the delivery of drug to the target of action and showed good neuronal activity.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-27T14:04:12Z
2021-09-27
2021-09-27T14:04:12Z
2021-07-07
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/bachelorThesis
format bachelorThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://riu.ufam.edu.br/handle/prefix/5968
url http://riu.ufam.edu.br/handle/prefix/5968
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv BAYSAL, Ipek et al. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. Journal of Neural Transmission, v. 124, n. 1, p. 33-45, 2017. BINDA, Anna; MURANO, Carmen; RIVOLTA, Ilaria. Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a state-of-the-art (2017– 2020). International Journal of Nanomedicine, v. 15, p. 6113, 2020. BURNS, Alistair et al. Cause of death in Alzheimer's disease. Age and ageing, v. 19, n. 5, p. 341-344, 1990. CRUCHO, Carina IC; BARROS, Maria Teresa. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Materials Science and Engineering: C, v. 80, p. 771-784, 2017. CANO, Amanda et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine, v. 15, n. 12, p. 1239-1261, 2020. CANO, Amanda et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, v. 301, p. 62-75, 2019. DANEMAN, Richard; PRAT, Alexandre. The blood–brain barrier. Cold Spring Harbor perspectives in biology, v. 7, n. 1, p. a020412, 2015. ELNAGGAR, Yosra SR et al. Intranasal piperine-loaded chitosan nanoparticles as braintargeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. Journal of pharmaceutical sciences, v. 104, n. 10, p. 3544-3556, 2015. FILHO, Ronaldo Pontes Barreira and Barreira, Idalbenia V. Barbosa P. (2017) Doença de Alzheimer: Diagnóstico e Perspectivas, Gramma, p. 168. FARJADIAN, Fatemeh et al. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine, v. 14, n. 1, p. 93-126, 2019. FOND, Guillaume; MACGREGOR, Alexandra; MIOT, Stéphanie. Nanopsychiatry—the potential role of nanotechnologies in the future of psychiatry: a systematic review. European neuropsychopharmacology, v. 23, n. 9, p. 1067-1071, 2013. GNACH, Anna et al. Upconverting nanoparticles: assessing the toxicity. Chemical Society Reviews, v. 44, n. 6, p. 1561-1584, 2015. GOATE, Alison et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, v. 349, n. 6311, p. 704-706, 1991. GNACH, Anna et al. Upconverting nanoparticles: assessing the toxicity. Chemical Society Reviews, v. 44, n. 6, p. 1561-1584, 2015. GELDMACHER, David S. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Primary care companion to the Journal of Clinical Psychiatry, v. 9, n. 2, p. 113, 2007. HARDY, John; SELKOE, Dennis J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. science, v. 297, n. 5580, p. 353-356, 2002. HUNT, Reid; DE M. TAVEAU, René. On the physiological action of certain cholin derivatives and new methods for detecting cholin. The British Medical Journal, p. 1788- 1791, 1906. HU, Ye et al. Nanodevices in diagnostics. Wiley interdisciplinary reviews: Nanomedicine and Nanobiotechnology, v. 3, n. 1, p. 11-32, 2011. IGARTÚA, Daniela E. et al. Combined therapy for alzheimer’s disease: tacrine and PAMAM dendrimers co-administration reduces the side effects of the drug without modifying its activity. AAPS PharmSciTech, v. 21, n. 3, p. 1-14, 2020. KARTHIVASHAN, Govindarajan et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug delivery, v. 25, n. 1, p. 307- 320, 2018. KRISHNA, Kowthavarapu Venkata et al. Design and biological evaluation of lipoproteinbased donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS chemical neuroscience, v. 10, n. 9, p. 4124-4135, 2019. KAUR, Atinderpal et al. Memantine nanoemulsion: a new approach to treat Alzheimer’s disease. Journal of microencapsulation, v. 37, n. 5, p. 355-365, 2020. LEVY-LAHAD, Ephrat et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, v. 269, n. 5226, p. 973-977, 1995. LOVELL, M. A. et al. Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the neurological sciences, v. 158, n. 1, p. 47-52, 1998. MAHMOUDI, Masomeh et al. Preparation and characterization of memantine loaded polycaprolactone nanocapsules for Alzheimer’s disease. Journal of Porous Materials, v. 28, n. 1, p. 205-212, 2021. MASSOUD, Fadi; LÉGER, Gabriel C. Pharmacological treatment of Alzheimer disease. The Canadian Journal of Psychiatry, v. 56, n. 10, p. 579-588, 2011. MANSOORI, G. Ali; SOELAIMAN, TA Fauzi. Nanotechnology—an introduction for the standards community. Journal of ASTM International, v. 2, n. 6, p. 1-22, 2005. MISRA, Shubham et al. Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug delivery, v. 23, n. 4, p. 1434-1443, 2016. NIEMIROWICZ, K. et al. Magnetic nanoparticles as new diagnostic tools in medicine. Advances in medical sciences, v. 57, n. 2, p. 196-207, 2012. NOBLE, Wendy; POOLER, Amy M.; HANGER, Diane P. Advances in tau-based drug discovery. Expert opinion on drug discovery, v. 6, n. 8, p. 797-810, 2011. PANZA, Francesco et al. Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?. Annals of neurology, v. 85, n. 3, p. 303-315, 2019. PAULA, Vanessa de Jesus R. de et al. Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dementia & neuropsychologia, v. 3, p. 188-194, 2009. PINHEIRO, R. G. R. et al. RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer’s disease. Pharmaceutical Research, v. 37, n. 7, p. 1-12, 2020. ROCO, Mihail C. International strategy for nanotechnology research. Journal of nanoparticle Research, v. 3, n. 5, p. 353-360, 2001. ROSS, Callum et al. Liposome delivery systems for the treatment of Alzheimer’s disease. International journal of nanomedicine, v. 13, p. 8507, 2018. SILMAN, Israel; SUSSMAN, Joel L. Acetylcholinesterase:‘classical’and ‘nonclassical’functions and pharmacology. Current opinion in pharmacology, v. 5, n. 3, p. 293- 302, 2005. SKAPER, Stephen D. Alzheimer’s disease and amyloid: culprit or coincidence. Int Rev Neurobiol, v. 102, p. 277-316, 2012. TOMA, Henrique Eisi. Nanotecnologia molecular: materiais e dispositivos. Editora Blucher, 2016. VIMAL, Sunil Kumar et al. Self‐Therapeutic Nanoparticle That Alters Tau Protein and Ameliorates Tauopathy Toward a Functional Nanomedicine to Tackle Alzheimer's. Small, v. 16, n. 16, p. 1906861, 2020. WOLFRAM, Joy et al. Safety of nanoparticles in medicine. Current drug targets, v. 16, n. 14, p. 1671-1681, 2015. YIANNOPOULOU, Konstantina G.; PAPAGEORGIOU, Sokratis G. Current and future treatments in Alzheimer disease: an update. Journal of central nervous system disease, v. 12, p. 1179573520907397, 2020.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Brasil
ICET - Instituto de Ciências Exatas e Tecnologia (Itacoatiara)
Manaus-AM
Farmácia - Bacharelado - Itacoatiara
publisher.none.fl_str_mv Brasil
ICET - Instituto de Ciências Exatas e Tecnologia (Itacoatiara)
Manaus-AM
Farmácia - Bacharelado - Itacoatiara
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFAM
instname:Universidade Federal do Amazonas (UFAM)
instacron:UFAM
instname_str Universidade Federal do Amazonas (UFAM)
instacron_str UFAM
institution UFAM
reponame_str Repositório Institucional da UFAM
collection Repositório Institucional da UFAM
repository.name.fl_str_mv Repositório Institucional da UFAM - Universidade Federal do Amazonas (UFAM)
repository.mail.fl_str_mv
_version_ 1798061055429050368

Registros relacionados